TGA Will Start Publishing GMP Inspection Outcomes
The Therapeutic Goods Administration (TGA) is changing how information about Good Manufacturing Practice (GMP) inspections is made available to the public. Following a consultation process in June and July 2026, the TGA confirmed that it will publish GMP inspection outcomes for Australian and international manufacturing sites. This represents a significant change in the visibility of manufacturing compliance and has practical implications for manufacturers, sponsors and organisations involved in the supply of therapeutic goods.
Historically, GMP inspection outcomes have primarily been communicated between the TGA and the manufacturer concerned. Although the TGA has published information about Australian manufacturers holding GMP licences, it has not routinely made inspection outcomes or equivalent information about overseas manufacturing sites publicly available.
That position is changing. Inspection outcomes will become accessible to a wider audience, including sponsors, customers, procurement teams and other industry stakeholders. Organisations should therefore consider how this increased transparency may affect supplier qualification, commercial relationships, regulatory oversight and their approach to maintaining GMP compliance.
When Will the TGA Start Publishing GMP Inspection Outcomes?
The legislative framework enabling publication has now been established.
The Therapeutic Goods (Information Specification—Manufacturing Inspections) Instrument 2026 was registered on the Federal Register of Legislation on 23 October 2026. The instrument commenced the following day, providing the legal basis for the public release of specified information about manufacturing inspections and GMP certificates.
The TGA's final approach is to publish inspection outcomes on a prospective basis. This means publication will apply to inspections conducted after the new arrangements commence. The TGA will not retrospectively publish outcomes from inspections conducted before implementation.
The TGA has also confirmed that information will be released through a routine monthly publication cycle. Publication is intended to occur once the inspection process has been completed and a final compliance outcome has been determined. Consequently, the inspection date and the date on which information becomes publicly available will not necessarily be the same.
The precise date of the first publication should be distinguished from the commencement of the legislative authority. The instrument is in force, but the TGA's publication process operates according to its implementation arrangements and monthly cycle. Organisations should monitor the TGA's announcements rather than assume that every completed inspection will appear online immediately.
Which Manufacturing Sites and Inspections Are Covered?
The arrangements cover GMP inspections of Australian and international manufacturers of therapeutic goods other than medical devices. This includes manufacturing sites inspected in Australia and overseas where the TGA conducts inspections relevant to the supply of therapeutic goods in Australia.
The information may relate to different types of inspections, including initial, routine and targeted inspections. The published information is intended to identify the manufacturing site and provide context about the activities assessed.
This is particularly relevant for sponsors that rely on overseas manufacturers. A manufacturer located outside Australia may be subject to TGA inspection and GMP certification processes even though it does not hold an Australian manufacturing licence. The new arrangements increase the visibility of these regulatory activities.
The publication framework also covers specified information from GMP certificates issued to overseas manufacturers. However, the TGA has adopted a modified presentation of certificate information rather than publishing the certificates themselves in their original format. This approach is intended to reduce the risk of unauthorised reproduction and avoid confusion between published information and an official certificate.
The changes do not mean that every laboratory, testing facility or organisation involved in the therapeutic goods supply chain will automatically have its inspection information published. The arrangements concern the specified categories of manufacturing inspection and GMP certificate information. Organisations should establish whether their activities fall within the relevant regulatory scope rather than assuming that all GMP-related assessments are covered.
What Information Will Be Made Public?
The published inspection information will provide a summary of the inspection and its final regulatory outcome. The information identified in the framework includes:
The manufacturer's name.
The manufacturer's licence or GMP certificate reference, where applicable.
The manufacturing site address or location.
The type and purpose of the inspection.
The date or period during which the inspection occurred.
The scope of manufacturing activities inspected.
The therapeutic goods manufactured at the site.
The manufacturing steps covered by the inspection.
Whether the manufacturer's GMP compliance outcome was acceptable or unacceptable.
The publication of these details provides more than a simple statement that a manufacturer has been inspected. It gives external stakeholders information about the site, the activities assessed and the final outcome determined by the regulator.
For overseas manufacturers, published GMP certificate information may also include relevant details such as the applicable GMP standard, certificate reference, issue date, expiry date where applicable, manufacturing activities and any limitations specified in the certificate.
An important point is that the published outcome will be either acceptable or unacceptable. It is not intended to provide a complete account of every deficiency identified during an inspection or reproduce the full compliance assessment.
What Will Not Be Published?
The distinction between an inspection outcome and a full inspection report is important.
The TGA is not proposing to publish detailed inspection reports, individual deficiencies, complete corrective and preventive action (CAPA) plans or commercially sensitive information. The publication framework is intended to provide defined regulatory information while protecting confidential business information.
For example, a published outcome should not be interpreted as a public record of every observation made by inspectors, every discussion held during an inspection or every corrective action agreed with the manufacturer.
This limitation matters because GMP inspections are detailed technical assessments. Inspectors may examine quality management systems, production operations, laboratory controls, validation, documentation, personnel practices, equipment, facilities and other areas relevant to the manufacturing activities under review.
The final outcome reflects the regulator's assessment after the inspection process has been completed. It does not communicate every technical detail considered in reaching that decision.
Manufacturers should therefore avoid treating the public record as a substitute for the full inspection report or for direct regulatory and quality oversight. Equally, sponsors should not assume that a publicly available summary contains sufficient information to replace their own supplier qualification and monitoring activities.
What Does This Mean for Australian Manufacturers?
For Australian manufacturers, the most immediate consequence is increased visibility of GMP inspection performance.
Previously, an inspection outcome was primarily relevant to the manufacturer, the TGA and parties with a legitimate need to obtain further compliance information. Under the new arrangements, the final outcome will be accessible to a broader audience.
This creates a stronger connection between regulatory compliance and commercial reputation. Sponsors may review published information when selecting manufacturing partners, evaluating existing suppliers or considering whether a manufacturing site remains suitable for a particular product or activity.
Procurement and quality teams may also use the information as an additional input into supplier risk assessments. An unacceptable outcome could prompt questions about the manufacturer's current compliance status, the scope of the inspection and the regulatory actions taken. An acceptable outcome may provide useful evidence of regulatory oversight, but it should not be interpreted as a guarantee that all future operations will remain compliant.
Manufacturers should also recognise that inspection outcomes are specific to the site and activities assessed. A result for one manufacturing location should not automatically be attributed to another site operated by the same company. Similarly, an outcome covering particular manufacturing steps does not necessarily provide assurance about activities outside the inspection scope.
The practical response is to strengthen continuous GMP compliance rather than focus exclusively on the next scheduled inspection.
What Does This Mean for Sponsors and Organisations Using Overseas Manufacturers?
Sponsors have a particular interest in the change because they remain responsible for exercising appropriate oversight of the manufacturers and suppliers supporting their products.
Published inspection information may provide another source of evidence when assessing an overseas manufacturing site. It can help confirm that the TGA has inspected a facility, identify the activities covered and indicate the final compliance outcome.
However, this information should be considered alongside existing supplier qualification arrangements. Sponsors should continue to review relevant GMP documentation, quality agreements, audit outcomes, manufacturing performance, deviations, change notifications and other information necessary to maintain oversight.
An acceptable published outcome does not remove the need for sponsor oversight. It also does not establish that every product manufactured at the site has been individually assessed or that the site is free from quality risks.
Where an unacceptable outcome is published, sponsors should assess its relevance to the products and activities for which the manufacturer is engaged. This may involve seeking further information through appropriate channels, reviewing the manufacturer's CAPA commitments and evaluating potential implications for product quality and supply continuity.
The publication arrangements may also influence supplier selection and procurement decisions. Organisations should ensure that commercial decisions are based on a balanced assessment of regulatory information, technical capability, product risk and the manufacturer's demonstrated performance.
Why Continuous Inspection Readiness Is Becoming More Important
Inspection readiness should be an ongoing operating condition, not a temporary project initiated when an inspection notification arrives.
A functioning GMP quality management system should provide evidence that manufacturing activities are controlled, responsibilities are understood and quality risks are identified and managed. This includes effective documentation, deviation management, CAPA, change control, supplier qualification, training, validation, equipment management and management oversight.
One area that deserves particular attention is the effectiveness of CAPA. Identifying a deficiency and documenting a proposed corrective action does not necessarily resolve the underlying problem. Organisations need to investigate root causes, implement appropriate actions and verify that those actions have prevented recurrence or reduced the identified risk.
Internal audits should examine how procedures operate in practice. They should identify weaknesses in process execution, documentation, technical controls and management oversight before those weaknesses become significant inspection findings.
Management review is equally important. Senior personnel should receive meaningful information about the effectiveness of the quality system, recurring deviations, overdue CAPAs, supplier performance, validation status, training and other indicators of GMP performance.
A system that operates effectively throughout the year is more likely to withstand regulatory scrutiny than one that is temporarily improved in response to an inspection schedule.
Preparing Your Organisation for Increased Transparency
Manufacturers and sponsors should begin by reviewing their existing compliance and supplier oversight arrangements.
For manufacturers, a practical first step is to conduct a structured assessment of the quality management system. This should identify weaknesses that could affect GMP compliance and determine whether existing controls are effective in routine operations.
The assessment should consider whether:
Procedures accurately reflect current manufacturing practices.
Personnel are trained and competent for their assigned responsibilities.
Deviations are investigated thoroughly and CAPA effectiveness is verified.
Changes are assessed and approved before implementation where required.
Equipment, facilities and utilities remain suitable for their intended use.
Validation and qualification activities are maintained in a controlled state.
Suppliers and outsourced activities receive appropriate oversight.
Internal audits identify meaningful issues and lead to effective improvements.
Management receives accurate information about quality system performance.
Manufacturers should also review their communication arrangements. Quality, regulatory and commercial teams need to understand how to respond if customers or sponsors ask questions about a published inspection outcome. Responses should be factual, consistent and supported by appropriate records. Organisations should not speculate about the meaning of an outcome or disclose confidential inspection information without authorisation.
Sponsors should review supplier monitoring procedures to determine how published TGA information will be considered within their existing risk management processes. Responsibility for reviewing relevant information should be assigned, and any concerns should be escalated through established quality and supplier management channels.
Interpreting Published Outcomes Correctly
A central challenge will be ensuring that published information is interpreted in its proper regulatory context.
An inspection outcome is a determination relating to a particular inspection, site and scope. It is not a comprehensive public assessment of every activity performed by a manufacturer, nor is it a permanent statement of compliance.
An acceptable outcome does not eliminate the possibility of future deficiencies. Manufacturing processes, personnel, equipment, suppliers and quality systems can change. Compliance must therefore be maintained through ongoing controls and oversight.
Similarly, an unacceptable outcome should not be interpreted without considering the inspection scope, the final regulatory determination and subsequent actions. The published summary will not provide the detailed information needed to understand every technical issue or the complete response undertaken by the manufacturer.
Sponsors and other stakeholders should use the information as one component of a broader assessment, not as a substitute for technical due diligence.
Turning Regulatory Transparency into an Opportunity to Improve
The TGA's decision to publish GMP inspection outcomes increases the visibility of manufacturing compliance in Australia and for overseas manufacturers supplying the Australian market. With the legislative instrument now in force, organisations should prepare for prospective publication through the TGA's routine monthly process.
For manufacturers, the change reinforces the importance of maintaining an effective quality system and demonstrating consistent GMP performance. For sponsors, it provides an additional source of regulatory information to support supplier oversight and risk-based decision-making.
Quality Systems Now works with therapeutic goods manufacturers, biotechnology organisations and testing laboratories to strengthen internal quality capability through practical QMS development, GMP training, internal audits, CAPA improvement and inspection readiness support.
The objective is to establish quality systems that work in daily operations, generate reliable evidence and support effective decision-making. As regulatory transparency increases, organisations with well-governed processes and a strong culture of quality will be better equipped to demonstrate control, respond to stakeholder questions and maintain confidence in their manufacturing operations.
